Drugs / Setidegrasib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07395024 | Feb → Jul 2026 overdue | — | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05382559 | Jun 2022 → Dec 2028 expected | cancer | Astellas Pharma Inc | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07566052 | Apr 2026 → Jun 2030 expected | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07409272 | Feb 2026 → Aug 2029 expected | pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-11 | Astellas Pharma Inc | Results Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 astellas.com ↗
The results support continued study of these investigational therapies for the treatment of various cancer types. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-23 | Astellas Pharma Inc | Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer astellas.com ↗ |
| 2026-04-14 | Astellas Pharma Inc | Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma astellas.com ↗ |
| 2024-09-11 | Astellas Pharma Inc | Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 astellas.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Setidegrasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07395024 ↗ |
| Modality | Other / unclassified | “Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader.” PMID 41879829 ↗ Mar 2026 |
| Route | Intravenous | “Setidegrasib was administered intravenously once weekly at doses of 10 to 800 mg.” PMID 41879829 ↗ Mar 2026 |
| Target | KRAS | “Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader.” PMID 41879829 ↗ Mar 2026 |